Pharmaceuticals

Health Tech By Erin Brodwin

How Amazon Pharmacy could ramp up pressure on the prescription drug industry

Pharmalot By Ed Silverman

FDA vows to disclose data used to support emergency drug authorizations

Health Tech By Erin Brodwin

Amazon, expanding its growing health empire, launches Amazon Pharmacy

Pharmalot By Ed Silverman

Federal authorities issue strong warning to pharma over speaker programs and kickbacks

Pharmalot By Ed Silverman

FDA requires Lilly to hire consultants to monitor quality control problems at plant making Covid-19 drug

Politics By Kate Sheridan

‘I don’t think it goes away’: Pharma experts weigh in on the next 4 years of drug pricing reform

Pharmalot By Ed Silverman

Americans are spending more on specialty medicines, despite rebates given to payers

pill construction site moral foundations theory

First Opinion By Karen Tibbals

Moral foundations theory can help rehabilitate pharma’s image

Pharmalot By Ed Silverman

Doctors are accepting as much money from industry as they were when OpenPayments launched

Pharma By Adam Feuerstein

Bristol’s novel treatment for psoriasis meets study goals, beats rival Amgen drug

First Opinion By Kao-Ping Chua, Adam Cifu, and Rena M. Conti

Spike in prescribing dexamethasone to Covid-19 patients may do more harm than good

The Pharmalot View By Ed Silverman

‘Where is Rudy?’: Inside Giuliani’s checkered track record as a pharma consultant

Don't Miss By STAT staff

As STAT turns 5, a look back at science and medicine’s biggest headlines and controversies

Biotech By Matthew Herper

Bayer to buy gene therapy company AskBio for as much as $4 billion

The Readout LOUD By Damian Garde and Adam Feuerstein

Listen: How the FDA thinks about Covid-19 vaccines, biotech’s SPAC fascination, & Biogen’s case in Alzheimer’s

Pharmalot By Ed Silverman

As Covid-19 intensifies, shortages of staple drugs may grow worse

Pharmalot By Ed Silverman

Purdue will plead guilty to federal charges, reaches $8.3 billion deal over opioid crisis

Pharmalot By Ed Silverman

A defiant AMAG wants an FDA hearing rather than withdraw its premature birth drug

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: A big week for pausing studies, pharma’s statehouse spending, & how HBCUs are approaching Covid-19 trials

Pharmalot By Ed Silverman

Vast majority of air cargo companies are unprepared to transport Covid-19 vaccines

First Opinion By Joy Sturm

Navigating the new ‘buy American’ drug landscape: opportunities for some, pitfalls for others

Special Report By Lev Facher

First-of-its-kind examination shows how widely pharma showers campaign cash at the state level

Health By Helen Branswell

First Ebola therapy approved by the FDA

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: ‘They gave me Regeneron’: How Trump’s case of Covid-19 affects biotech, medicine, and the FDA

First Opinion By Lisa Kearns, Alison Bateman-House, and Arthur L. Caplan

Most Read

Asthma drug from Amgen, AstraZeneca achieves main goals in late-stage clinical trial

Big study supports cheap combo pill to lower heart risks

For Eli Lilly’s newly authorized Covid-19 treatment, a dosing discrepancy causes confusion

Pharma is showering Congress with cash, even as drug makers race to fight the coronavirus

ViiV’s HIV prevention shot beats Gilead’s widely used pill in a study of women

Drug companies deliver a vote of confidence in adaptive trial for Covid-19

French regulator indicted for manslaughter for failing to respond to a drug’s side effects

Major generic makers will partner with Medicines Patent Pool to pursue voluntary licenses for Covid-19 drugs

All Coverage

How Amazon Pharmacy could ramp up pressure on the prescription drug industry

FDA vows to disclose data used to support emergency drug authorizations

Amazon, expanding its growing health empire, launches Amazon Pharmacy

Federal authorities issue strong warning to pharma over speaker programs and kickbacks

FDA requires Lilly to hire consultants to monitor quality control problems at plant making Covid-19 drug

‘I don’t think it goes away’: Pharma experts weigh in on the next 4 years of drug pricing reform

Americans are spending more on specialty medicines, despite rebates given to payers

Moral foundations theory can help rehabilitate pharma’s image

Doctors are accepting as much money from industry as they were when OpenPayments launched

Bristol’s novel treatment for psoriasis meets study goals, beats rival Amgen drug

Spike in prescribing dexamethasone to Covid-19 patients may do more harm than good

‘Where is Rudy?’: Inside Giuliani’s checkered track record as a pharma consultant

As STAT turns 5, a look back at science and medicine’s biggest headlines and controversies

Bayer to buy gene therapy company AskBio for as much as $4 billion

Listen: How the FDA thinks about Covid-19 vaccines, biotech’s SPAC fascination, & Biogen’s case in Alzheimer’s

As Covid-19 intensifies, shortages of staple drugs may grow worse

Purdue will plead guilty to federal charges, reaches $8.3 billion deal over opioid crisis

A defiant AMAG wants an FDA hearing rather than withdraw its premature birth drug

Listen: A big week for pausing studies, pharma’s statehouse spending, & how HBCUs are approaching Covid-19 trials

Vast majority of air cargo companies are unprepared to transport Covid-19 vaccines

Navigating the new ‘buy American’ drug landscape: opportunities for some, pitfalls for others

First-of-its-kind examination shows how widely pharma showers campaign cash at the state level

First Ebola therapy approved by the FDA

Listen: ‘They gave me Regeneron’: How Trump’s case of Covid-19 affects biotech, medicine, and the FDA

What President Trump’s ‘compassionate use’ of a Covid-19 drug means — and doesn’t mean

pharmaceuticals

Most Read

All Coverage